GlassScriptPhysician profile
Marc L Carroll
NPI 1639131329
$4,041.40
in general payments reported to CMS, 2019-2025
54 companies · $897 in 2025
The $897 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $407 · 2021: $35.62 · 2022: $332 · 2023: $1,080 · 2024: $796 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,683.03 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $340.46 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $320.44 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $213.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $196.17 | 2019-2025 | |
| Amgen INC. | $188.04 | 2019-2025 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $177.59 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $167.15 | 2019-2025 | |
| Abbott Laboratories | $151.52 | 2019-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $145.63 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $128.97 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $122.67 | 2022-2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $115.31 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $105.78 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.32 | 2023-2025 | Caplyta |
| Dexcom, INC. | $96.12 | 2022-2025 | Dexcom G6 Transmitter |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.